Press Releases

May 14, 2026 Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Read More
May 7, 2026 Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Read More
May 1, 2026 Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Read More
March 25, 2026 Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Read More
March 18, 2026 Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Read More
March 9, 2026 Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Read More
February 25, 2026 Celcuity To Participate in Upcoming Investor Conferences
Read More
February 12, 2026 Celcuity Appoints Charles Romp to its Board of Directors
Read More
February 4, 2026 Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
Read More
January 20, 2026 Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Read More